Docon Sells 9.9% Stake in Thyrocare for Rs 986 Crore
Docon Technologies divests nearly 10% of Thyrocare, reducing its stake to 51.02%.
In a significant transaction on Thursday, Docon Technologies, a major promoter of Thyrocare Technologies Ltd, sold a 9.9% stake in the diagnostics company for Rs 986 crore. The sale was executed through a series of bulk and block deals on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
Details of the Transaction
A total of 1,57,69,696 equity shares were offloaded by Docon, with the shares priced between Rs 624 and Rs 631.71 each. The bulk of the shares, over 1.31 crore, were sold through block deals, while an additional 10 lakh shares were traded through bulk deals on the NSE. Another 16.01 lakh shares were exchanged via a bulk deal on the BSE.
Following this transaction, Docon's holding in Thyrocare Technologies reduced from 60.92% to 51.02%. The sale saw participation from several institutional investors, insurance companies, and global investors, reflecting strong interest in the diagnostics chain.
Investor Participation
Prominent buyers included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Additionally, Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance were among the insurance firms that acquired shares. Global entities such as Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority also participated in the block deals on the NSE.
Thyrocare's stock responded positively to the news, with its shares rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE the following day.
Previous Transactions and Market Impact
This recent transaction follows Docon's previous sale of a 10% stake in Thyrocare for Rs 667 crore in October of the previous year. The consistent offloading of shares by Docon indicates a strategic realignment of its holdings in the diagnostics sector.
The stake sale underscores the ongoing interest and confidence in India's healthcare sector, as institutional and global investors continue to seek opportunities in this growing market. Thyrocare Technologies, a leading player in the diagnostics industry, remains a focal point for investment due to its extensive network and service offerings.